Clinical Trial Update: Opioid Relapse & HIV Risk: 48 Versus 24 Weeks of Injectable Extended Release Naltrexone [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial comparing 48 weeks versus 24 weeks of injectable extended-release naltrexone for opioid dependence with HIV risk, completed across Phase 2 and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Opioid Dependence

Drugs mentioned

• injectable extended-release naltrexone (naltrexone extended-release)

Snippet

Sponsor: University of Pennsylvania | Conditions: Opiate Dependence, Human Immunodeficiency Virus | Phase 2, Phase 3 | Status: COMPLETED